Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: LSE
Sector: Medical
Epic: VAL
News: Latest news
Web Site: ValiRx Plc
Other Articles: 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday July 29, 09:30Specialist Energy Group Lays Out a Compelling Blueprint for Growth

After a difficult start to life as a stock market listed company, the company now stands at the threshold of a much brighter future. Legacy issues have been dealt with and the turnaround programme initiated by CEO Ewan Lloyd-Baker is gaining traction.

FULL ARTICLE ► 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive AU ▼

Wednesday July 28, 11:30Silver Lake Resources boosts high grade gold resource by 70% to 2.5m ounces

Silver Lake Resources has added over 1 million ounces of gold to its resource inventory during the year after mining 66,700 ounces and expects further encouraging results at its  Mount Monger and Murchison projects.

FULL ARTICLE ► 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive CN ▼

Thursday July 15, 02:10Henan Yuguang Lead & Gold investment in Kimberley Metals receives all clear from FIRB

Kimberley Metals (ASX: KBL) has reported that on 12 July the Australian Government Foreign Investment Review Board (FIRB) had no objections to Henan Yuguang Lead & Gold Co. Ltd's [...]

FULL ARTICLE ►
ValiRx Plc

ValiRx Plc

Valirx Plc (Valirx) is a United Kingdom-based investment holding company. The Company, along with its subsidiaries, is engaged in therapeutic and diagnostic research and development. The Company is developing technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

Tuesday, March 09, 2010

ValiRx announces funding and partnership agreement

ValiRx PLC (AIM: VAL) said is has entered into a funding and commercial partnership agreement with the Laboratory of Government Chemistry (LGC) and Cambridge based drug developer Horizon Discovery. This partnership provides funding for the development of ValiRx's Hypergenomics technology into new gene activity based diagnostics and screening products. Financial details were not disclosed.

The partners are the end users of such tests and potential long term customers; this provides further product distribution networks for the technology. ValiRx has now completed a pilot development study and the goal of the agreement is to formulate new commercial products in the service and testing arena.

The company said the market potential is considerable for a method that offers whole genome screening. The cancer diagnostics market is predicted to be around US$6 billion in 2010 with the global epigenetic market estimated to be US$1.7 billion and growing 60 percent by 2012.

ValiRx has worldwide exclusive rights for the Hypergenomics technology and will retain the commercialisation rights for future products that arise under this agreement.

Successful tests should enable a variety of products centered on epigenetic mapping to be produced and ValiRx will develop service and product offerings focused on cancer and stem cell diagnostics and monitoring.

The principal applications will be the selection of optimal therapy regimes for patients, a key issue for pharmaceutical companies when conducting clinical trials and for follow on studies for companion diagnostics for approved drugs. Development of companion diagnostics is increasingly essential for the registration of new therapeutic products providing a much needed boost to pharma revenues.

The partners have wide contact networks within the pharmaceutical industry and it is anticipated that the tests will be marketed to these existing networks as well as to the wider pharma/biotech industry, ValiRx said.

As previously announced, the company continues to progress its epigenomic therapeutic approach with its GeneICE Eurostars consortium and has now reached the milestones associated with the third quarter of this programme.

LGC was founded in 1996 following the privatisation of the Laboratory of the Government Chemist, today LGC is owned by the management and staff and funds managed by the investment group LGV Capital. LGC retains its statutory role as Government Chemist, acting as the referee in cases where there is a dispute over analytical results or their interpretation.

AddThis Feed Button
Register here to be notified of future ValiRx Plc articles.

Investors interested in ValiRx Plc recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.